TransMedics provides tax valuation allowance impact: Q4 adjusted EPS $0.47

TransMedics Group, Inc.

2025-FY EPS reported $4.87 revenue$605,494,000

Released $103.3M U.S. tax valuation allowance in Q4, driving $83.8M net income tax benefit.
Annual effective tax rate 2025 was (77.0)%; without allowance release it would have been 19.1%.
Q4 pre-tax income $21.6M; reported net income $105.4M ($2.62 diluted EPS).
Adjusted net income after 19.1% tax rate: $17.5M ($0.47 diluted EPS).
Future quarters expected to have tax provision more in line with U.S. statutory rates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.